FDA Approves Novel Non-Stimulant Treatment for ADHD

Shares of Supernus Pharmaceuticals were climbing in premarket trading this morning after Friday’s announcement the U.S. Food and Drug Administration (FDA) approved the company’s non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.